Navigation Links
Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care

oellex, the Company's lead compound, a PRM (progesterone receptor modulator) has recently completed a successful U.S. three-month Phase 2 clinical trial for the treatment of uterine fibroids, a condition that affects numerous women of childbearing age in the United States and results in a significant number of hysterectomies each year. Proellex has recently completed a six-month European Phase 1/2 study for the treatment of endometriosis, a condition that affects approximately 5.5 million women in the United States and Canada. Androxal(TM), the Company's other program in late clinical development, is designed to restore normal testosterone production by the testes in men and has recently completed a six-month U.S. non-pivotal Phase 3 clinical trial for the treatment of testosterone deficiency due to secondary hypogonadism. According to industry sources, approximately 13 million men in the United States experience testosterone deficiency. The Company is planning meetings with the FDA for all three programs to lay out the remaining clinical program pathway required before a New Drug Application may be submitted for each product candidate.

For more information, please visit the Company's website at http://www.reprosrx.com.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to have success in the clinical development of its technologies, the timing of enrollment in such clinical studies and the accuracy of such studies, Repros' ability to raise additional capital on acceptable terms or at all, and such other risks which are identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, and Repros' Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, as they may be updated by the Company's Exchange Act filings from time to time. These documents are available on request from Repros Therapeutics or at
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:7/23/2014)... 2014 Pharmavite LLC announced that Timothy "Tim" ... effective immediately. Toll recently served as Pharmavite,s executive vice ... management, private label and sales administration in ... role, Toll will expand his responsibilities to include international ... "Toll,s appointment to chief customer officer is part of ...
(Date:7/23/2014)... , July 23, 2014 Research ... the "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation ... or destroy faulty electrical pathways from sections of ... known as cardiac arrhythmias). Cardiac arrhythmias can be ...
(Date:7/23/2014)... NEW YORK , July 23, 2014 /PRNewswire/ ... Delray Beach, Fla. , is an emerging ... molecular diagnostic systems for bio-threat detection and rapid ... system called M-BAND (Microfluidic Bio-agent Autonomous Networked Detector), ... of Homeland Security ("DHS") Science & Technology directorate, ...
Breaking Medicine Technology:Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2
... 31, 2011 Mevion Medical Systems announced today it ... S. Lee Kling Center for Proton Therapy at the ... University School of Medicine in St. Louis MO. This ... of the first MEVION S250 proton accelerator module and ...
... 31, 2011 Royal Philips Electronics (AEX: PHI, NYSE: ... full-field digital mammography (FFDM) solution that offers a lower ... compromising image quality. The addition of MicroDose to Philips, ... for the company,s focus on women,s health care, and ...
Cached Medicine Technology:Mevion Medical Systems Delivers the World's First Superconducting Synchrocyclotron for Proton Therapy to Barnes Jewish Hospital 2Philips Enters North American Mammography Market, Underscoring its Global Commitment to Women's Health Care 2Philips Enters North American Mammography Market, Underscoring its Global Commitment to Women's Health Care 3Philips Enters North American Mammography Market, Underscoring its Global Commitment to Women's Health Care 4
(Date:7/23/2014)... (PRWEB) July 23, 2014 Home ... in-home care for seniors, is proud to announce the ... featuring experts in a wide range of health and ... social worker and award-winning author Nancy Kriseman, and will ... ways to prevent burnout by becoming more self-aware. In ...
(Date:7/23/2014)... July 23, 2014 (HealthDay News) -- Regularly checking the ... stroke, researchers report. "Screening pulse is the method ... over age 65 who have never had a stroke. ... noninvasive and easy way to identify people who might ... said study author Dr. Bernd Kallmunzer, of Erlangen University ...
(Date:7/23/2014)... of Biomedical Imaging and Bioengineering will host its second ... 2014 on the NIH campus. There will be ten ... breadth of NIBIB-funded research. , WHO: ... Rhodopsins as Optical Voltage Sensor, Quyen Nguyen, Univ. ... Nerve Imaging during Surgery, ...
(Date:7/23/2014)... Global Cardio Care, Inc., a management company ... is celebrating the 100th birthday of Albert Weber, ... center. , Weber has been plagued with angina ... therapy since 1999, he no longer suffers from either ... Cardio Care, introduced the Sara Soulati Health For ...
(Date:7/23/2014)... Fragile X syndrome ( FXS ) is a genetic ... behaviors on the autistic spectrum, as well as cognitive ... mental impairment and the most common cause of autism. ... Riverside have published a study that sheds ... Appearing online today (July 23) in the Journal ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Routine Pulse Check May Prevent Second Stroke, Study Says 2Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3
... one day as part of cancer-fighting arsenal, but more study ... -- A new study in mice suggests that a transcription ... target for cancer vaccines. , A transcription factor is a ... from the DNA to messenger RNA. This particular factor, ...
... control of disease when chemo is targeted to specific ,molecular ... number one cancer killer, lung cancer, may be more susceptible ... with key genetic traits, a new study finds. , The ... overall, 46 percent of patients with stage IV (advanced) non-small ...
... Predicting breast cancer spread from a sentinel lymph node removed ... there are still many false negatives, which means the node, ... but metastasis can still occur in the patient. The sentinel ... cancer spreads to. Now, researchers from Georgetown Lombardi Comprehensive ...
... ... interactive feature, Keilhauer,s new microsite for Beam Seating makes specifying beam seating an easy ... ... Beam seating expand the original series to such an extent it can hardly be ...
... ... face trouble exercising and lifestyle restrictions, and more severe problems, like sleep apnea, can increase ... ... patients who report breathing problems are diagnosed with sinusitis, and many of these people find ...
... ... Cost Effective Occupational Health Care , ... Pittsburgh, PA (PRWEB) April 18, 2010 -- Allegheny Medical Integrated Health ... of physicians and health care professionals whose mission is to build better health for ...
Cached Medicine News:Health News:Vaccine Stops Tumor Spread in Mice 2Health News:Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes 2Health News:Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes 3Health News:Routine breast cancer biopsy might predict lymph node cancer spread 2Health News:Keilhauer's Expanded Beam Seating Launches With its Own Microsite 2Health News:Keilhauer's Expanded Beam Seating Launches With its Own Microsite 3Health News:Breathing Obstructions Caused by Sinusitis can Require Surgery, says Denver's Nose Doc 2Health News:Breathing Obstructions Caused by Sinusitis can Require Surgery, says Denver's Nose Doc 3Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 2Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 3
NS2000 Bipolar Generator provides precise coagulation without tissue sticking....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Standard bipolar coagulator...
Medicine Products: